Table 5.
Changes in Average Group Scores over Time for Primary (HRSD24) and Secondary (MADRS, IDS-SR30, and CGI-C) Outcome Measures with Corresponding Statistical Values, Functional Measures (Q-LES and MOS-SF36), and Average Psychotropic Drugsa
| Patients (n = 5) Mean Scores (SD) |
Repeated-Measure ANOVA |
Paired t Test |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Preop | Activation | 2 Weeks | 4 Months | 7 Months | df | F | p Value | Observed Power | Preop vs. 4 Months p Value | Preop vs. 7 Months p Value | |
| HRSD (24 Item) | 28.4 (4.8) | 29.8 (5.8) | 25.2 (11.5) | 19.4 (13) | 13 (11.4) | 4 | 4.867 | .009 | .879 | .092 | .037 |
| MADRS | 32 (7.6) | 31.2 (9.6) | 27 (6.2) | 22 (6.6) | 14.6 (6.1) | 4 | 3.886 | .022 | .683 | .075 | .043 |
| IDS-SR (30 Item) | 45.8 (16.2) | 43 (12.9) | 36.8 (19.1) | 31.4 (25.3) | 19 (18.48)a | 4 | 4.419 | .014 | .842 | .1 | .023 |
| CGI | 5.6 (1.14) | 5.2 (.8) | 4.8 (1.3) | 3 (1.2) | 3.4 (1.67) | 4 | 7.647 | .0001 | .981 | .075 | .043 |
| Q-LES | 40 (7.1) | — | — | 52 (20.9) | 50.4 (16.9) | ||||||
| MOS-SF36 | |||||||||||
| Physical functioning | 62 (21.96) | — | — | 71 (25.83) | 81 (12.94) | ||||||
| Role limit due to physical health | 0 | — | — | 0 | 0 | ||||||
| Role limit due to emotional problem | 0 | — | — | 0 | 0 | ||||||
| Energy/fatigue | 13 (10.36) | — | — | 32 (19.55) | 40 (22.63) | ||||||
| Emotional well-being | 36.8 (22.16) | — | — | 56.8 (38.09) | 67.2 (25.2) | ||||||
| Social functioning | 22.5 (18.54) | — | — | 50 (47.59) | 60 (45.41) | ||||||
| Pain | 67 (31.29) | — | — | 65.5 (23.41) | 69.5 (30.68) | ||||||
| General health | 50 (28.06) | — | — | 50 (31.62) | 66 (22.74) | ||||||
| Average Psychotropics | 6.23 | 6.4b (2.6) | 6.2b (2.28) | 6.4 (2.6) | 6.6 (2.3) | ||||||
ANOVA, analysis of variance; MADRS, Montgomery-Asberg Depression Scale; IDS-SR, Inventory of Depression Symptoms–Self-Report; CGI, Clinical Global Impression; Q-LES, Quality of Life, Enjoyment and Satisfaction Questionnaire; MOS_SF36, Medical Outcomes Study Short Form-36.
a
Patient 4 self-rating was 25.
b
Postoperative pain medications.